C

Cybin Inc
F:R7E1

Watchlist Manager
Cybin Inc
F:R7E1
Watchlist
Price: 13 EUR 17.12% Market Closed
Market Cap: 9.9B EUR

Relative Value

There is not enough data to reliably calculate the relative value of R7E1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

R7E1 Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
-141.6
Median 5Y
-284.2
Industry
21.4
Forward
-17.8
vs History
vs Industry
Median 3Y
-130
Median 5Y
-292.8
Industry
16.4
vs History
vs Industry
Median 3Y
-152.3
Median 5Y
-274.8
Industry
22.8
vs History
69
vs Industry
Median 3Y
52.2
Median 5Y
285
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-127
Median 5Y
-262.9
Industry
13
Forward
-146.7
vs History
vs Industry
Median 3Y
-126.3
Median 5Y
-261.6
Industry
16.5
Forward
-147.9
vs History
vs Industry
Median 3Y
-127.8
Median 5Y
-292.2
Industry
15.6
vs History
vs Industry
Median 3Y
-126.5
Median 5Y
-274.2
Industry
18.7
vs History
82
vs Industry
Median 3Y
119.4
Median 5Y
426.5
Industry
1.9

Multiples Across Competitors

R7E1 Competitors Multiples
Cybin Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cybin Inc
F:R7E1
5.5B EUR 0 -62.4 -51.6 -51.5
US
Eli Lilly and Co
NYSE:LLY
1.1T USD 17.7 57.3 38.6 41.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
500.7B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
269.6B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
221.5B GBP 5.1 31.6 108.8 159.3
CH
Novartis AG
SIX:NOVN
219.5B CHF 4.9 19.1 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
277.7B USD 4.3 14.5 10.3 12.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.2 15.8 11 12.8
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.7B USD 2.3 14.6 7.5 10.2
P/S Multiple
Revenue Growth P/S to Growth
CA
C
Cybin Inc
F:R7E1
Average P/S: 72
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
17.7
26%
0.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
9%
64.3
US
Johnson & Johnson
NYSE:JNJ
5.4
6%
0.9
CH
Roche Holding AG
SIX:ROG
4.4
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
5.1
8%
0.6
CH
Novartis AG
SIX:NOVN
4.9
5%
1
US
Merck & Co Inc
NYSE:MRK
4.3
4%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
5.2
5%
1
IE
E
Endo International PLC
LSE:0Y5F
92.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.3
-2%
N/A
P/E Multiple
Earnings Growth PEG
CA
C
Cybin Inc
F:R7E1
Average P/E: 25.2
Negative Multiple: -62.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
57.3
54%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.8
3%
5.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
C
Cybin Inc
F:R7E1
Average EV/EBITDA: 440.2
Negative Multiple: -51.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.6
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
C
Cybin Inc
F:R7E1
Average EV/EBIT: 1 883.8
Negative Multiple: -51.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.4
36%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5